Citadel Advisors LLC Has $4.35 Million Stake in Penumbra, Inc. (PEN)
Citadel Advisors LLC lifted its stake in Penumbra, Inc. (NYSE:PEN) by 2.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,568 shares of the company’s stock after acquiring an additional 959 shares during the period. Citadel Advisors LLC owned approximately 0.15% of Penumbra worth $4,350,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of PEN. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Penumbra by 10.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,159 shares of the company’s stock worth $102,000 after acquiring an additional 114 shares during the period. Ameritas Investment Partners Inc. bought a new position in shares of Penumbra in the first quarter worth $194,000. FNY Partners Fund LP bought a new position in shares of Penumbra in the first quarter worth $223,000. Prudential Financial Inc. bought a new position in shares of Penumbra in the second quarter worth $252,000. Finally, Citigroup Inc. boosted its holdings in shares of Penumbra by 284.8% in the second quarter. Citigroup Inc. now owns 2,990 shares of the company’s stock worth $262,000 after acquiring an additional 2,213 shares during the period. 70.93% of the stock is owned by hedge funds and other institutional investors.
Shares of Penumbra, Inc. (NYSE:PEN) opened at 89.60 on Thursday. Penumbra, Inc. has a 1-year low of $56.05 and a 1-year high of $91.00. The company’s 50-day moving average price is $85.75 and its 200 day moving average price is $84.49. The company has a market cap of $3.03 billion, a price-to-earnings ratio of 605.41 and a beta of 0.09.
Penumbra (NYSE:PEN) last issued its earnings results on Tuesday, August 8th. The company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). The company had revenue of $80.60 million during the quarter, compared to the consensus estimate of $77.16 million. Penumbra had a negative net margin of 2.78% and a negative return on equity of 2.58%. Penumbra’s quarterly revenue was up 23.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.01 EPS. On average, analysts predict that Penumbra, Inc. will post ($0.21) earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on the company. BidaskClub lowered Penumbra from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Canaccord Genuity reissued a “buy” rating and set a $94.00 price objective on shares of Penumbra in a research note on Tuesday, June 13th. BMO Capital Markets reissued a “buy” rating and set a $96.00 price objective on shares of Penumbra in a research note on Friday, June 16th. Finally, Zacks Investment Research raised Penumbra from a “sell” rating to a “hold” rating in a research note on Wednesday, August 30th.
ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/28/citadel-advisors-llc-has-4-35-million-stake-in-penumbra-inc-pen.html.
In related news, insider Daniel Donen Davis sold 32,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $79.42, for a total value of $2,541,440.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Thomas Wilder sold 345 shares of the company’s stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $86.10, for a total transaction of $29,704.50. The disclosure for this sale can be found here. Insiders sold a total of 54,687 shares of company stock valued at $4,500,350 in the last ninety days. 22.00% of the stock is currently owned by insiders.
Penumbra Company Profile
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN).
Receive News & Stock Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related stocks with our FREE daily email newsletter.